| 前收盘价格 | 0.828 |
| 收盘价格 | 1.10 |
| 成交量 | 610 |
| 平均成交量 (3个月) | 1,754 |
| 市值 | 3,452,861 |
| 价格/销量 (P/S) | 3.04 |
| 股市价格/股市净资产 (P/B) | 7.34 |
| 52周波幅 |
| 营业利益率 (TTM) | -1,590.14% |
| 稀释每股收益 (EPS TTM) | -8.88 |
| 季度收入增长率 (YOY) | 160.00% |
| 总债务/股东权益 (D/E MRQ) | 6.97% |
| 流动比率 (MRQ) | 0.500 |
| 营业现金流 (OCF TTM) | -16.19 M |
| 杠杆自由现金流 (LFCF TTM) | -11.54 M |
| 资产报酬率 (ROA TTM) | -376.08% |
| 股东权益报酬率 (ROE TTM) | -759.09% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Vaccinex, Inc. | - | - |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | -1.00 |
|
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company’s lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer’s Disease, with ongoing exploration of potential Phase 3 development in Huntington’s disease. The firm has also developed a proprietary drug discovery platform, ActivMAb. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 11.51% |
| 机构持股比例 | 45.01% |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合